Li-Kuo Su, Editor-in-Chief of Cancer Cell will join us at the Hotel Alimara, Monday 14 January 2013, 09:00 – 10:15, to deliver the 5th in VHIO´s prestigious series of VHIO Meet the Editors talks:
Cancer Cell and the Cancer Research Community
Related Posts
Marking Breast Cancer Awareness Month 2014: VHIO and the Vall d´Hebron University Hospital launch series of workshops for breast cancer patients
Barcelona, 16 October 2014. The Vall d´Hebron Institute of Oncology (VHIO) and the Vall d´Hebron University Hospital (HUVH) have joined…
16 Oct 2014
VHIO Spin-Off Mosaic Biomedicals co-recipient of CataloniaBio´s Biosuccess Award of the Year
Wednesday night´s annual Night of CataloniaBio gala event convening some 250 entrepreneurs, executives, investors, and leading scientists from within the…
17 Mar 2017
VHIO collaborates in study identifying a novel therapeutic target for triple-negative breast cancer
• The PIM1 proto-oncogene evidenced as new therapeutic target through which to sensitize triple-negative breast tumours to chemotherapy• PIM1…
05 Nov 2016
ecancerTV/SABCS 2015 interview: Javier Cortes discusses efficacy and gene expression results from eribulin neoadjuvant study
At the recent annual San Antonio Breast Cancer Symposium (SABCS), 8 – 12 December, San Antonio, USA, the ecancerTV team…
04 Jan 2016
Study led by VHIO reports most promising improvement in advanced breast cancer survival
The Cleopatra study reports improvement in median survival of almost 16 months in patients with HER2-positive metastatic breast cancer The…
11 Mar 2015
VHIO´s Javier Cortes comments: Two Anti-HER2 Antibodies Better than One
A recent paper published in The New England Journal of Medicine, shows that Pertuzumab, an anti-HER 2 antibody, recognizes a different epitope of HER2 than Trastuzumab and behaves differently. In patients with metastatic breast cancer, the combination of the two antibodies plus docetaxel significantly increased progression-free survival.
A recent paper published in The New England Journal of Medicine, shows that Pertuzumab, an anti-HER 2 antibody, recognizes a different epitope of HER2 than Trastuzumab and behaves differently. In patients with metastatic breast cancer, the combination of the two antibodies plus docetaxel significantly increased progression-free survival.
Co-author Javier Cortés, Principle Investigator of VHIO´s Breast Cancer and Melanoma Group, describes the CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) randomized trial, the importance and implications of the findings, as well as signposts future directions.
29 Dec 2011
Warm reception for Barcelona Clinical Trials Platform (BCTP) at Farmaindustria
Source: Biocat Yesterday, 27 June 2015, the Catalan Ministry of Health and Biocat presented their joint initiative Barcelona Clinical Trials…
28 May 2015
VHIO brings breaking data to Stockholm: the 2011 European Multidisciplinary Cancer Congress
Aflibercept vs placebo and FOLFIRI for MCRC
06 Oct 2011
Multi-center study led by CIC bioGUNE reveals metabolic pathway implicated in prostate cancer growth
Published in Nature journal today, a multi-center study led by CIC bioGUNE´s Arkaitz Carracedo, Ikerbasque Research Professor, Associate Professor at the…
29 Jun 2017
An independent nationwide evaluation ranks Vall d´Hebron´s Medical Oncology Service top of the leaderboard
According to the first independent, benchmark evaluation of the Spanish healthcare sector, Monitor de Reputación Sanitaria (MRS), issued by the…
04 Dec 2014
Marking melanoma cancer awareness month: Vall d´Hebron updates on its multidisciplinary and purely translational approach to more effectively treating this tumor type
The incidence of melanoma skin cancers has been substantially increasing over the past decades with an estimated 132,000 cases occurring…
23 May 2017
A new treatment, fresh hope and future horizons for metastatic breast cancer patients in Spain
Officially announced today, Halaven ® (Eribulin) has received reimbursement approval from the Spanish Directorate General of Pharmacy and Health Products,…
05 Sep 2013
2016 independent nationwide evaluation ranks Vall d´Hebron´s Medical Oncology Department top of the leaderboard for third consecutive year
According to a third independent, annual benchmark evaluation of the Spanish healthcare sector, Monitor de Reputación Sanitaria (MRS), issued by…
14 Dec 2016
SPECTAcolor: driving biomarker discovery and the development of novel therapies against advanced colorectal cancer
Incorporating over 20 clinical centers and research entities across 11 countries, including the Catalan Institute of Oncology (ICO) and the…
20 Mar 2015
Susan G. Komen awards 900.000 US$ to support VHIO research aimed at advancing insight in breast cancer
Barcelona, 23 September, 2015.– Susan G. Komen has awarded two Vall d´Hebron Institute of Oncology (VHIO) researchers with Career Catalyst…
23 Sep 2015
